Australia's Race Oncology jumps on encouraging results from cancer drug trial

Racura Oncology

30/06/2022 04:37

** Shares of pharma co Race Oncology  RAC.AX  climb as much
as 12.9% to A$2.1, their highest level since June 1
    ** Co says its cancer drug Zantrene can protect mice hearts
from permanent damage caused by anthracyclines, an anti-cancer
treatment  urn:newsml:reuters.com:*:nASX57NJJp
    ** Stock posts its biggest intraday pct. gain since June 21
    ** Says results are from a preclinical cardioprotection
program that has been undertaken with the University of
Newcastle
    ** Co says new findings are the first evidence of its kind
to show there's a therapy that targets cancer while protecting
the heart
    ** Says the results support future clinical trials using
Zantrene in combination with anthracyclines to improve cancer
patient treatment
    ** RAC down 48.3% YTD, as of last close 
    


 (Reporting by Riya Sharma in Bengaluru)
 ((Riya.Sharma@thomsonreuters.com;))